The Columbia Collaborative HIV/AIDS Clinical Trials Unit (Columbia Collaborative CTU) brings together a dedicated and cohesive group of investigators and two institutions situated in New York City (NYC), one of the epicenters of the US epidemic. This collaboration includes highly experienced investigators and two successful clinical research sites (CRSs) with breadth and depth of expertise in clinical, translational and behavioral HIV research to be responsive to the rapidly evolving research needs in HIV prevention (including passive immunization with single, combination of multiple or multi-specific broadly neutralizing monoclonal antibodies, vaccines, novel antiretroviral-based approaches, and integrated biomedical and socio-behavioral strategies) and HIV therapeutics (including antibodies and long-acting antiretroviral formulations, and antiretroviral-free approaches to remission, biobehavioral interventions to improve adherence and reduce the risk of treatment failure, in addition to tuberculosis, complications and comorbidities), as defined by the Division of AIDS (DAIDS) Clinical Trials Networks (CTNs).
Despite great progress in HIV prevention and treatment, many questions remain to be addressed. The Columbia Collaborative HIV/AIDS Clinical Trials Unit is located in a hot spot of HIV activity and is perfectly positioned to conduct cutting edge clinical trials and contribute to scientific agendas of the DAIDS-sponsored Clinical Trials Networks.
Showing the most recent 10 out of 122 publications
